Login / Signup

Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.

Daniela PuglieseLuisa GuidiGiuseppe PriviteraLorenzo BertaniBarbara TolussoLuigi Giovanni PapparellaSimona MaltintiClara Di MarioSara OnaliLinda CeccarelliGian Lodovico RapacciniFranco ScaldaferriElisa GremeseAntonio GasbarriniFrancesco CostaAlessandro Armuzzi
Published in: Expert opinion on biological therapy (2020)
Switching from infliximab originator to CT-P13 seems safe and effective, without differences in immunogenicity. A temporary reduction of clinical benefit after switching could be potentially explained by a 'nocebo-effect response'.
Keyphrases